TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28684261

Group type: EXPERIMENTAL
Intervention: Healthy volunteers (HRM with SWS and rice STM)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Patients with major motility disorders
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Healthy volunteers
Number of subjects: 179

Group type: COMPARATOR
Intervention: Patients with dysphagia
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: HRM with SWS and rice STM
Number of subjects: 179
Study: 28684371

Group type: EXPERIMENTAL
Intervention: Fludarabine therapy
Number of subjects: 133
Study: 28684537

Group type: EXPERIMENTAL
Intervention: Pomalidomide (4 mg by mouth on days 1 to 21), bortezomib (1.0 mg/m2 IV or subcutaneous), dexamethasone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 28685151

Group type: EXPERIMENTAL
Intervention: Gestational diabetes mellitus (GDM)
Number of subjects: 820

Group type: EXPERIMENTAL
Intervention: Lower parity and higher educational levels
Number of subjects: 820
Study: 28685159

Group type: EXPERIMENTAL
Intervention: Molecular screening using Ion Torrent sequencing platform
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Ion Torrent sequencing
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Illumina sequencing technology for validation
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Ion Torrent sequencing for copy number aberrations
Number of subjects: 41
Study: 28685410

Group type: EXPERIMENTAL
Intervention: Youths with ASD
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Unaffected siblings
Number of subjects: 198

Group type: COMPARATOR
Intervention: Typically Developing Controls (TD)
Number of subjects: 198
Study: 28685973

Group type: EXPERIMENTAL
Intervention: Exenatide QWS-AI (2 mg)
Number of subjects: 375

Group type: COMPARATOR
Intervention: Exenatide BID (10 μg)
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Exenatide QWS-AI
Number of subjects: 375
Study: 28686124

Group type: EXPERIMENTAL
Intervention: Convection-enhanced delivery (CED) with a radiolabeled antibody
Number of subjects: 1
Study: 28687077

Group type: EXPERIMENTAL
Intervention: Plasma levels of ITLN1 after myocardial ischemia
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: mRNA expression of ITLN1 in left ventricular tissue after acute ischemia
Number of subjects: 140
Study: 28687231

Group type: EXPERIMENTAL
Intervention: Mepolizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Different controller therapies
Number of subjects: 0
Study: 28687349

Group type: EXPERIMENTAL
Intervention: Lung cancer screening and tobacco cessation program; details on dosage and duration not available.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group; details not available.
Number of subjects: 0
Study: 28687625

Group type: EXPERIMENTAL
Intervention: Ofatumumab (OFA) infusion at an accelerated regimen: 300 mg on week 1 day 1, 1,000 mg on week 1 day 3, 2,000 mg on week 2 day 1, followed by weekly infusions for 8 weeks and monthly for 4 months.
Number of subjects: 34
Study: 28687627

Group type: EXPERIMENTAL
Intervention: Sorafenib and capecitabine combination therapy
Number of subjects: 15
Study: 28687936

Group type: EXPERIMENTAL
Intervention: LUTS prevalence in men
Number of subjects: 8284

Group type: EXPERIMENTAL
Intervention: LUTS prevalence in women
Number of subjects: 8284

Group type: EXPERIMENTAL
Intervention: LUTS prevalence by age
Number of subjects: 8284

Group type: EXPERIMENTAL
Intervention: Presence of all three ICS symptom groups
Number of subjects: 8284

Group type: EXPERIMENTAL
Intervention: Most prevalent symptoms
Number of subjects: 8284

Group type: EXPERIMENTAL
Intervention: Most bothersome symptoms
Number of subjects: 8284

Group type: EXPERIMENTAL
Intervention: IPSS scores
Number of subjects: 8284

Group type: EXPERIMENTAL
Intervention: Healthcare visits due to urinary symptoms
Number of subjects: 8284
Study: 28688730

Group type: EXPERIMENTAL
Intervention: Medical Orders for Scope of Treatment (MOST) documentation
Number of subjects: 370
Study: 28689185

Group type: EXPERIMENTAL
Intervention: Person-centred integrated heart failure and palliative care at home
Number of subjects: 12
Study: 28689278

Group type: EXPERIMENTAL
Intervention: Maternal serum total Homocysteine (tHcy) measured at 15-19 weeks
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Uterine artery (Ut-A) Doppler performed at 18-22 weeks
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Combination of tHcy assessment and Ut-A Doppler
Number of subjects: 500
Study: 28689333

Group type: EXPERIMENTAL
Intervention: Direct exposure to ribavirin during pregnancy or 6 months prior (85 women)
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Indirect exposure to ribavirin through male partners (95 women)
Number of subjects: 272
Study: 28690539

Group type: EXPERIMENTAL
Intervention: NeurimmiRs intervention (specific details not provided)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (specific details not provided)
Number of subjects: 0
Study: 28690586

Group type: EXPERIMENTAL
Intervention: Standard therapy (radiotherapy and chemotherapy)
Number of subjects: 50
Study: 28690642

Group type: EXPERIMENTAL
Intervention: Icatibant
Number of subjects: 448

Group type: COMPARATOR
Intervention: Long-term prophylaxis (LTP)
Number of subjects: 448
Study: 28690682

Group type: EXPERIMENTAL
Intervention: ABM-MNCs transplantation
Number of subjects: 7
Study: 28690851

Group type: EXPERIMENTAL
Intervention: ER + M group (emotion regulation and mindfulness skills)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 75
Study: 28691333

Group type: EXPERIMENTAL
Intervention: Gas-based cryotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thermal coagulation
Number of subjects: 0
Study: 28691436

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) initiated at day 0 of AHI; specific dosage not mentioned.
Number of subjects: 265

Group type: COMPARATOR
Intervention: No treatment (untreated AHI)
Number of subjects: 265
Study: 28691931

Group type: COMPARATOR
Intervention: Topical gentamicin (0.1% ointment applied 3 times daily for 2 weeks)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Intradermal gentamicin (8 mg solution injected daily for 2 days)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo (topical and intradermal)
Number of subjects: 5
Study: 28692407

Group type: EXPERIMENTAL
Intervention: Medication-assisted treatment (MAT)
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Outpatient counseling only
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Residential treatment
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: No formal treatment (Narcotics Anonymous/Alcoholics Anonymous or halfway house)
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: No postdetoxification treatment
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: History of drug overdose
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Sex
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Homelessness
Number of subjects: 440
Study: 28692954

Group type: EXPERIMENTAL
Intervention: Personality-targeted interventions
Number of subjects: 154
Study: 28693058

Group type: EXPERIMENTAL
Intervention: lenalidomide
Number of subjects: 0
Study: 28693366

Group type: EXPERIMENTAL
Intervention: Idarucizumab (5 g intravenous)
Number of subjects: 503
Study: 28693491

Group type: EXPERIMENTAL
Intervention: Pre-hospital tracheal intubation (TI) by physician-staffed HEMS
Number of subjects: 1265
Study: 28693521

Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation program
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Pulmonary physiotherapy (PPT)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Parenteral nutrition
Number of subjects: 181

Group type: COMPARATOR
Intervention: Control group (no pulmonary rehabilitation)
Number of subjects: 181
Study: 28693755

Group type: EXPERIMENTAL
Intervention: Disorganized symptoms
Number of subjects: 1391

Group type: EXPERIMENTAL
Intervention: Illness insight
Number of subjects: 1391

Group type: EXPERIMENTAL
Intervention: Neurocognition
Number of subjects: 1391

Group type: EXPERIMENTAL
Intervention: Negative symptoms
Number of subjects: 1391
Study: 28693934

Group type: EXPERIMENTAL
Intervention: Essential Frailty Toolset (EFT)
Number of subjects: 1020
Study: 28694253

Group type: EXPERIMENTAL
Intervention: Compassion Intervention led by an interdisciplinary care leader (ICL) for 6 months
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Interdisciplinary care leader (ICL) hours
Number of subjects: 30
Study: 28694340

Group type: EXPERIMENTAL
Intervention: Not applicable (observational study)
Number of subjects: 0
Study: 28694343

Group type: EXPERIMENTAL
Intervention: Beta blockers non-withdrawal during acute heart failure
Number of subjects: 5005

Group type: EXPERIMENTAL
Intervention: Beta blockers non-withdrawal during acute heart failure (ADCHF only)
Number of subjects: 5005

Group type: EXPERIMENTAL
Intervention: Beta blockers non-withdrawal
Number of subjects: 5005

Group type: COMPARATOR
Intervention: Beta blockers withdrawal
Number of subjects: 5005
Study: 28694834

Group type: COMPARATOR
Intervention: Influenza vaccine
Number of subjects: 76
Study: 28694840

Group type: EXPERIMENTAL
Intervention: Low fat (LF) diet
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Low glycemic index (LGI) diet
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Very low carbohydrate (VLC) diet
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Dietary intervention (general)
Number of subjects: 21
Study: 28694991

Group type: EXPERIMENTAL
Intervention: 12-week, home-based, online-streamed yoga intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 28696231

Group type: EXPERIMENTAL
Intervention: Nafithromycin 800 mg once daily for 3 days
Number of subjects: 37
Study: 28697406

Group type: EXPERIMENTAL
Intervention: Indomethacin or ibuprofen (or both)
Number of subjects: 3587

Group type: COMPARATOR
Intervention: Control group (z-score <-2)
Number of subjects: 3587
Study: 28697693

Group type: EXPERIMENTAL
Intervention: VBX Stent Graft
Number of subjects: 134
Study: 28697762

Group type: EXPERIMENTAL
Intervention: Cash transfer intervention
Number of subjects: 1214
Study: 28698106

Group type: EXPERIMENTAL
Intervention: Loss in knee extensor strength in women concurrent with symptomatic progression
Number of subjects: 1785

Group type: EXPERIMENTAL
Intervention: Loss in knee flexor strength in women concurrent with symptomatic progression
Number of subjects: 1785

Group type: COMPARATOR
Intervention: Loss in knee extensor strength in women without symptomatic progression
Number of subjects: 1785

Group type: COMPARATOR
Intervention: Loss in knee flexor strength in women without symptomatic progression
Number of subjects: 1785

Group type: EXPERIMENTAL
Intervention: Loss in knee extensor and flexor strength concurrent with radiographic progression
Number of subjects: 1785

Group type: EXPERIMENTAL
Intervention: Prior change in muscle strength with symptomatic or radiographic progression
Number of subjects: 1785
Study: 28698323

Group type: EXPERIMENTAL
Intervention: hs-TnT assay at T0
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: hs-TnT assay at T2
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: hs-TnT assay at T6
Number of subjects: 48
Study: 28698330

Group type: EXPERIMENTAL
Intervention: Biological therapy (specific biologic agent not mentioned)
Number of subjects: 60
Study: 28698343

Group type: EXPERIMENTAL
Intervention: Delirium assessment at 30 min and 60 min following tracheal tube removal using the 3-min Diagnostic Confusion Assessment Method and the Richmond Agitation and Sedation Scale.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Delirium assessment over postoperative days 1-5 using the Confusion Assessment Method (CAM), CAM for the Intensive Care Unit, and structured chart review.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Logistic regression analysis to test the predictive value of immediately postoperative delirium.
Number of subjects: 100
Study: 28698344

Group type: EXPERIMENTAL
Intervention: PA/MD model (physician assistants and medical doctors)
Number of subjects: 2292

Group type: COMPARATOR
Intervention: MD model (only medical doctors)
Number of subjects: 2292
Study: 28698603

Group type: EXPERIMENTAL
Intervention: Differentially methylated BRCA1 and CRISP2 regions
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Differentially methylated regions (DMR) related to impaired oxidative stress, DNA repair, and inflammatory pathways
Number of subjects: 16
Study: 28699212

Group type: EXPERIMENTAL
Intervention: Live births (9 cases)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Terminations (5 cases)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Perinatal deaths (2 cases)
Number of subjects: 16
Study: 28699419

Group type: EXPERIMENTAL
Intervention: Five times chair rise test
Number of subjects: 267
Study: 28699641

Group type: EXPERIMENTAL
Intervention: Nilotinib (300 to 400 mg twice daily)
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Nilotinib dose escalation for lack of efficacy
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Nilotinib dose reduction due to adverse events
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Nilotinib re-escalation after dose reduction
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Nilotinib
Number of subjects: 421
Study: 28700265

Group type: EXPERIMENTAL
Intervention: Quadrivalent influenza vaccine (IIV4)
Number of subjects: 675

Group type: COMPARATOR
Intervention: Trivalent influenza vaccine (IIV3) containing B Victoria-lineage strain
Number of subjects: 675

Group type: COMPARATOR
Intervention: Trivalent influenza vaccine (IIV3) containing B Yamagata-lineage strain
Number of subjects: 675
Study: 28700272

Group type: EXPERIMENTAL
Intervention: MiniMed 640G insulin pump
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Guardian Connect system
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: GSR-connected arm sensors
Number of subjects: 88
Study: 28701316

Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin I (hs-cTnI)
Number of subjects: 1631

Group type: COMPARATOR
Intervention: Contemporary cardiac troponin I (cTnI)
Number of subjects: 1631

Group type: COMPARATOR
Intervention: Contemporary cTnI ≤99th percentile at 0, 3, and 6 h with normal ECG
Number of subjects: 1631

Group type: EXPERIMENTAL
Intervention: hs-cTnI measurements ≤99th percentile at 0 and 3 h with normal ECG
Number of subjects: 1631

Group type: COMPARATOR
Intervention: Contemporary cTnI measurements
Number of subjects: 1631

Group type: EXPERIMENTAL
Intervention: Contemporary cTnI with serial changes (delta, 0 and 6 h) >150%
Number of subjects: 1631

Group type: EXPERIMENTAL
Intervention: hs-cTnI with serial testing at 0 and 3 h
Number of subjects: 1631

Group type: EXPERIMENTAL
Intervention: hs-cTnI with delta hs-cTnI (0 and 3 h) >5 ng/L
Number of subjects: 1631
Study: 28701371

Group type: EXPERIMENTAL
Intervention: Biomarker screening pathway using C-peptide and islet autoantibodies
Number of subjects: 1407

Group type: EXPERIMENTAL
Intervention: Biomarker screening pathway
Number of subjects: 1407
Study: 28701470

Group type: EXPERIMENTAL
Intervention: Ferric Carboxymaltose (FCM) for 24 weeks
Number of subjects: 172

Group type: COMPARATOR
Intervention: Standard of care (control)
Number of subjects: 172
Study: 28701487

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 5795

Group type: EXPERIMENTAL
Intervention: Coronary-artery bypass grafting (CABG)
Number of subjects: 5795

Group type: COMPARATOR
Intervention: Medication alone
Number of subjects: 5795
Study: 28701528

Group type: EXPERIMENTAL
Intervention: Systolic Blood Pressure (SBP) 100-129 mm Hg
Number of subjects: 2141

Group type: EXPERIMENTAL
Intervention: Systolic Blood Pressure (SBP) 130-170 mm Hg
Number of subjects: 2141
Study: 28701572

Group type: EXPERIMENTAL
Intervention: Panel-based sequencing program
Number of subjects: 418
Study: 28701571

Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel (150 mg/m2 weekly for four cycles)
Number of subjects: 81
Study: 28702218

Group type: EXPERIMENTAL
Intervention: 1000-calorie deficit feeding and exercise intervention (CR)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Weight management counseling intervention (WM)
Number of subjects: 21
Study: 28702228

Group type: COMPARATOR
Intervention: Lifestyle intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lifestyle intervention (DPPOS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metformin (DPPOS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lifestyle and Metformin
Number of subjects: 0
Study: 28702291

Group type: EXPERIMENTAL
Intervention: Neonatal pneumococcal conjugate vaccine
Number of subjects: 88
Study: 28702844

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA)
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH)
Number of subjects: 434

Group type: COMPARATOR
Intervention: No anticoagulation
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: Combination of ASA and LMWH
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: Untreated urinary tract infection (UTI)
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: History of cardiovascular disease
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: Therapeutic dose of LMWH
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: ASA medication
Number of subjects: 434
Study: 28702877

Group type: EXPERIMENTAL
Intervention: Volixibat
Number of subjects: 8
Study: 28704280

Group type: EXPERIMENTAL
Intervention: Transient WRF
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Persistent WRF
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: BNP decrease less than 30%
Number of subjects: 192
Study: 28704412

Group type: EXPERIMENTAL
Intervention: Synthetic PreImplantation Factor (PIF)
Number of subjects: 0
Study: 28704603

Group type: EXPERIMENTAL
Intervention: Infrapatellar fat pad morphology in painful knees of subjects with unilateral knee pain
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Infrapatellar fat pad morphology in chronically painful knees
Number of subjects: 132
Study: 28705148

Group type: EXPERIMENTAL
Intervention: Structured peer support (Mentor Mother)
Number of subjects: 497

Group type: COMPARATOR
Intervention: Unstructured peer support (routine)
Number of subjects: 497
Study: 28705182

Group type: EXPERIMENTAL
Intervention: Carboplatin and paclitaxel with concurrent radiotherapy (41.4-45 and 50.4 Gy)
Number of subjects: 0
Study: 28705184

Group type: EXPERIMENTAL
Intervention: POC IADPSG testing
Number of subjects: 616

Group type: EXPERIMENTAL
Intervention: POC 1-h 50 g GCT (≥7.2 mmol/L [129.6 mg/dL])
Number of subjects: 616

Group type: EXPERIMENTAL
Intervention: Other POC tests
Number of subjects: 616

Group type: COMPARATOR
Intervention: IADPSG testing
Number of subjects: 616
Study: 28705187

Group type: EXPERIMENTAL
Intervention: Home-based rehabilitation with physiotherapy (mean of ten sessions)
Number of subjects: 473

Group type: COMPARATOR
Intervention: Initial BI
Number of subjects: 473
Study: 28705310

Group type: EXPERIMENTAL
Intervention: 3D vascular ultrasound (3DVUS)
Number of subjects: 3860
Study: 28705532

Group type: EXPERIMENTAL
Intervention: Galantamine-memantine combination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 28705547

Group type: EXPERIMENTAL
Intervention: Closed incision negative pressure therapy (ciNPT)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Traditional gauze dressing
Number of subjects: 192
Study: 28705613

Group type: EXPERIMENTAL
Intervention: Eccentric exercise rehabilitation (REHAB) following 5-days of bed rest
Number of subjects: 23

Group type: COMPARATOR
Intervention: Bed rest
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Eccentric exercise rehabilitation (REHAB)
Number of subjects: 23
Study: 28705939

Group type: EXPERIMENTAL
Intervention: Exercise echocardiography and cardiopulmonary exercise testing at baseline and follow-up
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exercise right heart catheter (RHC) investigations (subgroup)
Number of subjects: 0
Study: 28706089

Group type: EXPERIMENTAL
Intervention: Geriatric Fracture Centre (GFC)
Number of subjects: 266

Group type: COMPARATOR
Intervention: Usual Care Centres (UCC)
Number of subjects: 266
Study: 28706090

Group type: EXPERIMENTAL
Intervention: Standardised, objective multistep method for site selection
Number of subjects: 266
Study: 28706103

Group type: EXPERIMENTAL
Intervention: Vitamin D metabolites and associated hormones measurements in AKI patients
Number of subjects: 230

Group type: COMPARATOR
Intervention: Vitamin D metabolites and associated hormones measurements in non-AKI patients
Number of subjects: 230
Study: 28706500

Group type: EXPERIMENTAL
Intervention: Physical activity indices
Number of subjects: 1129

Group type: EXPERIMENTAL
Intervention: Motor skills
Number of subjects: 1129
Study: 28706563

Group type: EXPERIMENTAL
Intervention: OFC (6/25-12/50 mg/day olanzapine/fluoxetine)
Number of subjects: 255

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 255
Study: 28707175

Group type: EXPERIMENTAL
Intervention: Syndemic score
Number of subjects: 772

Group type: EXPERIMENTAL
Intervention: Immigrant generation
Number of subjects: 772

Group type: EXPERIMENTAL
Intervention: Separated orientation
Number of subjects: 772
Study: 28707316

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 50

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 50
Study: 28707359

Group type: EXPERIMENTAL
Intervention: Pedometer tracking of daily steps
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Accelerometer wear time
Number of subjects: 149
Study: 28707983

Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 8034

Group type: COMPARATOR
Intervention: Normal lung density regions
Number of subjects: 8034

Group type: EXPERIMENTAL
Intervention: ND-E/I ratio
Number of subjects: 8034
Study: 28707987

Group type: EXPERIMENTAL
Intervention: Caffeine treatment
Number of subjects: 142

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 142
Study: 28708290

Group type: EXPERIMENTAL
Intervention: Preferential adaptive left ventricular-only pacing with the AdaptivCRT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 28708962

Group type: EXPERIMENTAL
Intervention: Ad5-EBOV (one shot intramuscular injection)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Ad5-EBOV (double-shot regimen)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Ad5-EBOV (both groups)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Ad5-EBOV (high-dose group)
Number of subjects: 61
Study: 28709412

Group type: EXPERIMENTAL
Intervention: Propranolol 0.2% eye micro-drops treatment until retinal vascularization is completed, but for no longer than 90 days.
Number of subjects: 0